Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
4
×
Tags
biotech
boston blog main
eli lilly
fda
indiana blog main
indiana top stories
lasmiditan
4
×
life sciences
national blog main
raleigh-durham blog main
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
migraine
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
triptans
wisconsin blog main
wisconsin top stories
amgen
cancer
cancer immunotherapy
colucid pharmaceuticals
galcanezumab
migraine research foundation
What
new
approval
bio
companies
decades
drug
drugs
fda
life
migraine
pharmaceutical
roundup
science
won
acute
addresses
arena’s
arguments
bails
big
bounty
brand
bridgebio
capital
car
causes
cig
class
comeback
commercialized
competitors
condition
corner
deals
delivered
develop
eli
emerges
expressing
firm
Language
unset
Current search:
lasmiditan
×
photo
×
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
